# FREEDOM2 (NCT03952039)

> An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03952039
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Celgene
- Conditions: Primary Myelofibrosis; Post-Polycythemia Vera; Myelofibrosis
- Interventions: FEDRATINIB; Best Available Therapy (BAT)
- Enrollment: 202
- Primary outcome: Spleen Volume Response Rate (RR)

## Commentary we found

- YouTube: 23
- Podcasts: 13
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=freedom2-nct03952039

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03952039", "email": "<work email>"}; the inbox owner confirms by the emailed link.